Follow us on Twitter
twitter icon@FreshPatents


Fatty Liver patents

      

This page is updated frequently with new Fatty Liver-related patent applications.




 Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states patent thumbnailSelf-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect.
Sancilio & Company, Inc.


 2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof patent thumbnail2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof
2-alkoxy benzene formyl arylamine compounds and their pharmaceutical salts are disclosed. The compounds can act as sphingomyelin synthase (sms) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin (sm).
Fudan University


 Cenicriviroc for the treatment of fibrosis patent thumbnailCenicriviroc for the treatment of fibrosis
The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvate thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (nafld), or emerging cirrhosis..
Tobira Therapeutics ,inc.


 Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof patent thumbnailNonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided.
Somalogic, Inc.


 A peptide therapy to counteract insulin resistance and type 2 diabetes patent thumbnailA peptide therapy to counteract insulin resistance and type 2 diabetes
Compositions comprising an antagonist of pancreastatin are provided. The beneficial use of the compositions for treating insulin resistance, diabetes, especially type ii diabetes, inflammation, obesity, non-alcoholic fatty liver disease, atherosclerosis and cardiovascular diseases is described as well..
Indian Institute Of Technology Madras


 Novel lactic acid bacterium and composition including said lactic acid bacterium patent thumbnailNovel lactic acid bacterium and composition including said lactic acid bacterium
The present invention provides a lactobacillus that improves hyperuricemia, fatty liver and a lifestyle-related disease, and a composition containing the lactobacillus.. .
Nitto Pharmaceutical Industries, Ltd.


 Prevention and treatment of non-alcoholic fatty liver disease patent thumbnailPrevention and treatment of non-alcoholic fatty liver disease
Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. Methods for inhibiting excessive accumulation of fat in liver tissue.
Ohio University


 Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations patent thumbnailBacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations
The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products.
Consejo Superior De Investigaciones Cientificas


 Treatment and prevention of liver disease associated with parenteral nutrition (pn) patent thumbnailTreatment and prevention of liver disease associated with parenteral nutrition (pn)
The present invention is based on the discovery that parenteral nutrition (pn) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with pn rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid.
Children's Medical Center Corporation


 Compositions and methods for treating diabetes and liver diseases patent thumbnailCompositions and methods for treating diabetes and liver diseases
Compounds, compositions, and methods are described herein for treating diabetes, fatty liver diseases, fibrotic diseases, such as liver and pulmonary fibrosis, and hepatocellular carcinoma.. .
Cempra Pharmaceuticals, Inc.


Inhibitors of the farnesoid x receptor and uses in medicine

Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid x receptor in a mammal, and a method of treating or preventing obesity in a mammal..
The Penn State Research Foundation

Systems and methods for detecting a fatty liver from a computed tomography (ct) scan

There is provided a computer-implemented method for detecting a fatty liver, comprising: receiving imaging data of a computed tomography (ct) scan performed using a single source ct scanner with settings selected for imaging of non-fatty-liver pathology, segmenting a region of the liver by creating a binary image by applying binary segmentation to a sub-set of pixels of the imaging data according to a first set-of-rules, and mapping the region of liver of the binary image to the segmented region of the portion of the liver of the imaging data, calculating liver parameter(s) for the segmented region of the liver from hounsfield unit (hu) value(s), and detecting the presence of a fatty liver by analyzing the calculated liver parameter(s) according to a second set-of-rules.. .

Calcitonin mimetics for treating diseases and disorders

Calcitonin mimetic peptides having an amino acid sequence in accordance with seq id no:8 or seq id no:53, each of which may be carboxylated at its n-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its c-terminal, and in each of which the 1 and 7 position cysteine residues may together be replaced by α-aminosuberic acid (asu) are useful as medicaments for treating diabetes (type i and/or type ii), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poorly regulated of food intake.. .

Pharmaceutical compositions of berberine with epa and dha, and methods thereof

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity.
Shenzhen Hightide Biopharmaceutical, Ltd.

Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of general formula (i) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease..
Genfit

7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld)

The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (nafld), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis.
Gw Pharma Limited

Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a dlk1-fc fusion protein constructed by conjugation of an extracellular domain of dlk1 or a fragment thereof with a human antibody fc region. Also provided are health functional foods containing a dlk1-fc fusion protein constructed by conjugation of an extracellular domain of dlk1 (delta-like 1 homolog) or a fragment thereof with a human antibody fc region as an active ingredient..
Industry-academic Cooperation Foundation, Yonsei University

Engineered polypeptides having enhanced duration of action

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
Astrazeneca Pharmaceuticals Lp

Thyromimetics for the treatment of fatty liver diseases

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.. .
Metabasis Therapeutics, Inc.

Composition for preventing and treating non-alcoholic fatty liver diseases

A composition includes a black chokeberry extract and at least one of a thistle extract, a black hoof mushroom extract and a mixture thereof. The composition is effective in preventing and treating non-alcoholic fatty liver disease caused by accumulation of fat in the liver due to excessive intake of nutrients or metabolic syndrome regardless of alcohol intake.
Jbk Natural Medicine Institute

Method and system for treating non-alcoholic fatty liver disease

A method and system for treating non-alcoholic fatty liver disease (nafld) involves the modulation of the gut microbial of a person suffering from nafld, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, tnf-α and to improve insulin resistance in nafld patients.. .

Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine

Methods of treating patients suffering from non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), including those also suffering front type ii diabetes mellitus (t2dm), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.. .
Hadasit Medical Research Services And Development Ltd.

Novel composition for nonalcoholic fatty liver disease (nafld)

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited

Pharmaceutical composition for controlling blood lipids and body weight, and use thereof

The invention provides a traditional chinese medicine composition for the control of blood lipids and/or weight of body, which includes poria and paeoniae radix alba, etc. The traditional chinese medicine composition can be applied in reducing the total cholesterol level, triacylglycerol level, and low density lipoprotein cholesterol level in the body; increasing body high density lipoprotein cholesterol level, reducing uric acid level, and/or reducing symptoms of fatty liver.
Beijing Hebabiz Management Co., Ltd.

Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example nash, nafld, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (mace) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span..
Janssen Pharmaceutica Nv

Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (nafld), and other metabolic disorders, and various lipodystrophies such as hiv-haart induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients..
Novartis Ag

Crystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease

The present invention relates to the composition comprising crystalline xylose-isomerase and at least one salt of a metal and/or alkaline earth metal for the treatment and prevention of non-alcoholic fatty liver disease and other fructose-related disorders.. .
Sciotec Diagnostic Technologies Gmbh

Methods for treating metabolic disorders using fgf

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies

Mitochondrial-derived peptide mots3 regulates metabolism and cell survival

Mots3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using mots3 and pharmaceutical compositions thereof are disclosed herein..
The Regents Of The University Of California

Pharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver disease

The present invention relates to a pharmaceutical composition containing a g protein coupled receptor 119 (gpr119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the gpr119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the gpr119 ligand can be useful to treat non-alcoholic fatty liver..
Snu R&db Foundation

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University

Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders.
Shenzhen Hightide Biopharmaceutical, Ltd.

Composition for preventing or treating fatty liver diseases

The present invention relates to a pharmaceutical composition for preventing or treating fatty liver diseases, containing (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof as active ingredients. (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof, according to the present invention, can effectively inhibit fatty liver, hepatitis and hepatic fibrosis and can be useful for preventing or treating nafld, and in particular, nash..
Lg Life Sciences Ltd.

Method to prepare ganoderma lucidum polysaccharides possessing protective activities on fatty liver disease

The present invention provides a method to prepare polysaccharides from ganoderma lucidum. The prepared polysaccharides can reduce liver weight and liver lipid content in humans and animals.
Chang Gung Biotechnology Corp.

Free raptor reduces aging- and obesity-induced fatty liver

The present invention also provides a method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that inhibits glucagon signaling in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride. .

Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes.

In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to rygb surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.. .

Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and t2d

In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to rygb surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.. .

Systems, devices and methods for performing medical procedures in the intestine

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element.
Fractyl Laboratories, Inc.

Method for assessment of hepatic function and portal blood flow

A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the stat test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate.
The Regents Of The University Of Colorado, A Body Corporate

Use of a statin compound as topical drug for treating obesity, diabetes, hypertension and hyperlipemia

The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.. .
Peking University Third Hospital

Modulation of nlgn4 expression, nk cell activity in non-alcoholic fatty liver disease (nafld)

The present invention provides a method of diagnosing and/or monitoring a liver disorder in a subject. The method calls for isolating an immune cell population from a biological sample of the subject; and detecting expression level of an nlgn4 gene product in the immune cell population using nlgn4 specific primers or nlgn4 specific probes..
Hadasit Medical Research Services And Development Ltd.

Glucagon and glp-1 co-agonist compounds

The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).. .
Eli Lilly And Company

Lysosomal acid lipase therapy for nafld and related diseases

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating the metabolic syndrome.
Children's Hospital Medical Center

Method to prepare hirsutella sinensis polysaccharides possessing protective activities on fatty liver disease

The present invention provides a method to prepare polysaccharides from hirsutella sinensis. The prepared polysaccharides can reduce liver size, weight and the number and size of liver lipid vacuoles, as well as serum triglycerides and serum aspartate aminotransferase levels in humans and animals.
Chang Gung Biotechnology Corp.

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis

5-cholesten, 3β, 25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virginia Commonwealth University

Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease

The present invention relates to the field of gene therapy and, more particularly, to methods for the prevention and/or treatment of non-alcoholic fatty liver disease (nafld). The viral vectors disclosed in the present invention are preferably parvoviral vector, more preferably adeno-associated vectors (aav) containing the gene encoding sirtuin 1 (sirt1) in the prevention and/or treatment of nafld.
Universitat Autònome De Barcelona

Methods for treating metabolic disorders using fgf

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies

Ketohexokinase (khk) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the ketohexokinase (khk) gene, and methods of using such rnai agents to inhibit expression of khk and methods of treating subjects having a khk-associated disorder, e.g., liver disease (e.g., fatty liver, steatohepatitis), dyslipidemia (e.g., hyperlipidemia, high ldl cholesterol, low hdl cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (e.g., insulin resistance, diabetes), cardiovascular disease (e.g., hypertension, endothelial cell dysfunction), kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.. .
Alnylam Pharmaceuticals, Inc.

Methods for the treatment and prevention of renal disorders and fatty liver disorders

The present invention is directed to methods for treating, delaying, slowing the progression of and/or preventing disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) canagliflozin and (b) one or more ace inhibitors or one or more arbs or one or more ppar-gamma agonists; and to methods for treating, delaying, slowing the progression of and/or preventing fatty liver disorders (for example, nash or nafld), comprising administering to a subject in need thereof a therapeutically effective amount of canagliflozin.. .
Janssen Pharmaceutica Nv

Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2..
Duke University

Pomegranate skin extract for treating fatty liver

Use of a pomegranate skin extract for use in the treatment of metabolic syndrome, more particularly, fatty liver disease. More particularly, the pomegranate skin extract is used in inhibiting body weight gain in the prevention and/or the treatment of fatty liver disease in mammals..
Nestec S.a.

Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders

This invention is in the area of improved anti-ap2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone ap2/fabp4 (referred to as “ap2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for ap2 mediated disorders are disclosed in which serum ap2 is targeted and the biological activity of ap2 is neutralized or modulated using low-binding affinity ap2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease..
Ucb Biopharma Sprl

Methods for treating fatty liver disease

In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an actriib signaling pathway. Examples of such antagonists include actriib polypeptides, anti-actriib antibodies, anti-myostatin antibodies, anti-gdf3 antibodies and anti-activin a or b antibodies.
Acceleron Pharma Inc.

Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient

A biguanide derivative compound with n1-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampkα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..
Immunomet Therapeutics Inc.

Chemical ablation and treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, nonalcoholic fatty liver disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients.
Neurotronic, Inc.

Differential diagnosis of liver disease

The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (nash) from nonalcoholic fatty liver (nafl) and non-nonalcoholic fatty liver disease (nafld), and normal controls.
The Regents Of The University Of California

Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect.
Sancilio & Company, Inc.

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
Volant Holdings Gmbh

Continuous arycyclic compound

This is to provide a continuous arycyclic compound having a dgat1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a dgat1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof..
Mitsubishi Tanabe Pharma Corporation

Method for treating or preventing nonalcoholic fatty liver disease

A method for treating or preventing non-alcoholic fatty liver disease is disclosed. By promoting the expression of six-transmembrane protein of prostate 2 (stamp2) in liver cells, the method can be useful in improving the abnormalities in lipid metabolism in the liver, and also improving insulin resistance, thereby preventing or treating a non-alcoholic fatty liver disease..
Dong-a University Research Foundation For Industry- Academy Cooperation

Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g.
Virginia Commonwealth University

Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (nafld) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective pparγ agonist, int131 and optionally vitamin e or compositions thereof. Naflds that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (nash).
Intekrin Therapeutics, Inc.

Prevention and treatment of non-alcoholic fatty liver disease

Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. The methods include administering a therapeutically effective amount of phenylmethimazole, methimazole derivatives, and/or tautomeric cyclic thiones to the subject.
Ohio University

Method for protection and improvement of liver health with meso-zeaxanthin compositions

A method for protection, treatment and improvement of liver health includes administering a meso-zeaxanthin composition in an effective amount to a subject in need thereof. In particular, methods are described of administering a meso-zexanthin composition to a subject fed with high fat diet (hfd), and studying the effect of meso-zeaxanthin for treatment of fatty liver condition, through evaluation of various parameters such as biochemical indicators, anti-inflammatory markers, and nutritional markers..
Omniactive Health Technologies Limited

Methods and materials for treating diabetes or liver steatosis

This document provides methods and materials for treating diabetes and/or liver steatosis. For example, methods for using compositions containing a potato polysaccharide preparation to reduce one or more symptoms of diabetes or liver steatosis are provided.
The Research Foundation For The State University Of New York

Composition and methods for treating intestinal hyperpermeability

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

Metformin salts to treat type2 diabetes

Metformin salts of 2,4-thiazolidinediones are described for the treatment of diabetes mellitus type2, gestational diabetes, polycystic ovary syndrome, non-alcoholic fatty liver disease, coronary artery disease, pancreatic cancer, premature puberty, and other diseases which manifest insulin resistance.. .
Jiva Pharma, Inc.

Engineered polypeptides having enhanced duration of action and reduced immunogenicity

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.

Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same

Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, alzheimer's disease, parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided.
Concordia University

Diagnosis and treatment of incipient diabetes

A method is described for predicting incipient diabetes, metabolic disorders or the metabolic syndrome by developing a personal temporal phosphatase profile, which is generated by measuring phosphatase concentration in stool at a single time-point or multiple time-points. The phosphatase profile further can be used for diagnosing and determining prognosis of other incipient or overt diseases, such as the metabolic syndrome, coronary heart disease, nonalcoholic fatty liver disease, cancers, other chronic or acute diseases or infectious diseases.

Composition for treating hyperlipidemia comprising oxyntomodulin derivative

The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate glp-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio.
Hanmi Pharm. Co., Ltd.

Novel 2,4-dinitrophenol formulations and methods using same

The present invention includes a low dose and sustained release formulation of 2,4-dinitrophenol (dnp). The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof..
Yale University

Compositions and methods for treating intestinal hyperpermeability

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

Fat accumulation inhibitor, drug, prophylactic or therapeutic agent for fatty liver, food or drink, and producing fat accumulation inhibitor

A fat accumulation inhibitor includes, as an active ingredient, a plant belonging to the genus cirsium.. .

Methods for treating or preventing fatty liver disease using ctrp3

Methods are disclosed for treating or preventing fatty liver disease using a ctrp3 polypeptide or functional variant thereof.. .

Biaryl derivatives as gpr120 agonists

The present invention relates to biaryl derivatives of formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of formula 1 according to the present invention promote glp-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation..
Lg Life Sciences Ltd.

A novel composition for nonalcoholic fatty liver disease (nafld)

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited

Inhibitors of the farnesoid x receptor and uses in medicine

Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least cone compound of the invention, a method of method of inhibiting a farnesoid x receptor in a mammal, and a method of treating or preventing obesity in a mammal..
The Penn State Research Foundation

Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash)..
The Regents Of The University Of California

Chi3l1 for the detection and treatment of nonalcoholic steatohepatitis

Disclosed herein are compositions and methods for detecting nonalcoholic steatohepatitis (nash) measuring chi3l1 levels. In some embodiments, the methods described herein can distinguish nash from nonalcoholic fatty liver disease.
Yale University

Engineered polypeptides having enhanced duration of action

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
Aegerion Pharmaceuticals, Inc.

Drug for treatment of nonalcoholic fatty liver disease

The present invention provides a compound useful in the prevention and treatment of nonalcoholic fatty liver disease. The invention relates to a drug for the prevention and/or treatment of nonalcoholic fatty liver disease, the drug having as an active ingredient (r)-2-[3-[[n-(benzoxazol-2-yl)-n-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate of these..
Kowa Company, Ltd.

Pharmaceutical composition and health functional food containing red ginseng concentrate having enhanced compound k for preventing and treating non-alcoholic fatty liver disease

The present invention relates to a pharmaceutical composition and a health functional food composition for preventing and treating non-alcoholic fatty liver disease, which comprises red ginseng concentrate having enhanced compound k as an effective ingredient by using an enzyme conversion technique.. .
Cj Cheiljedang Corporation

Modulation of nlgn4 expression, nk cell activity in non-alcoholic fatty liver disease (nafld)

The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting ngn4 expression and thereby modulating the activity of nk cells. The present invention further relates to diagnosing a liver disorder by evaluating nlgn4 expression in nk cells..
Hadasit Medical Research Services And Development Ltd.

Co-agonists of the glucagon and glp-1 receptors

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase iv (dpp-iv) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (glp-1) receptor and the glucagon (gcg) receptor, and the use of such glp-1 receptor/gcg receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (nafld), non-alcoholic steatohepatitis (nash), and obesity.. .
Merck Sharp & Dohme Corp.

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.. .

Highly soluble leptins

The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type i and type ii).
Aegerion Pharmaceuticals, Inc.

New aryl-quinoline derivatives

Wherein r1, r2, r3, r4, r5, r6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (fabp) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases..

Methods for regulating transcription of multiple genes and expression of multiple targets

This invention discloses methods for regulating multiple organs, multiple genes and multiple targets by using a polypeptide, wherein the polypeptide comprising the amino acid sequence of seq id no.1 and/or homology thereof. The present polypeptide reveals the potency to regulate transcription of multiple genes and expression of multiple targets.
China Medical University

Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of general formula (i) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease..
Genfit

Novel fatty acids and their use in conjugation to biomolecules

Wherein r1, r2, r3, r4, ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as gdf15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.

Notch1 decoy antagonists protect from obesity-induced insulin resistance and fatty liver

(b) instructions for using the pharmaceutical composition of step (a) to treat the fatty liver disease.. .

Compositions and methods for treating non-alcoholic steatohepatitis

The disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic; has normal or substantially normal biliary tract function; or has non or early stage hepatocyte apoptosis; and administering a therapeutically effective amount of a pharmaceutical composition comprising epas.. .
Mochida Pharmaceutical Co., Ltd.

Biomarkers for fatty liver disease and methods using the same

The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease..
The Cleveland Clinic Foundation

Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient

A biguanide derivative compound with n4-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampk and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..
Hanall Biopharma Co., Ltd.

Methods to screen compounds for regulating usf1 activity and methods and compounds to treat cardiometabolic and lipid pathologies

The deficiency of usf1 confers a remarkable number of clinically relevant beneficial metabolic effects in mice via activation of brown adipose tissue. The usf1 deficient mice have high serum hdl-cholesterol and low triglyceride levels, a beneficial lipid profile opposite to that of human metabolic syndrome.
Terveyden Ja Hyvinvoinnin Laitos (thl)

Methods for treating metabolic disorders using fgf

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies

Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof

Provided herein are oral pharmaceutical compositions containing a glp-1 analogue and/or insulin for treating and reducing the incidence of nonalcoholic fatty liver disease (nafld), hepatic steatosis, and sequelae thereof and methods of utilizing same.. .
Oramed Ltd.

Novel beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient

The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of dgat1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis..
Handok Pharmaceuticals Co., Ltd.

Stable micelles of fatty acid esters for the treatment of non-alcoholic fatty liver diseases

Described herein are compositions comprising at least one omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one omega-3 fatty acid ester and at least one surface active agent, wherein the at least one omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one omega-3 fatty acid ester is substantially independent of a food effect.
Sancilio & Company, Inc.

Nasal vaccine against the development of atherosclerosis disease and fatty liver

The present invention provides a novel vaccine compound of micellar nanoparticles to be administered intranasally to treat and/or prevent the disease called atherosclerosis, which results from an abnormal metabolism of circulating lipids. The novelty of the vaccine compound of the present invention is the use of archaebacterian lipids, lysophosphatidylcholine, and phosphatidylcholine, which give nanoparticles stability and facilitates antigen presentation in its appropriate secondary peptidic conformation.
Universidad Nacional AutÓnoma De MÉxico

Use of ivermectin and derivatives thereof

The present invention relates to the new use of antiparasitic agents, such as ivermectin, abamectin/avermectin, doramectin and so on, and the design method of the derivatives for the new use. The said compounds including macrolide abamectin/avermectin, ivermectin, doramectin and the derivatives thereof, may be used in the manufacture of a medicament for use in treating metabolic related diseases in a mammal, such as hyperglycemia, insulin resistance, hypertriglyceridemia, hypercholesterolemia, diabetes, obesity, etc, and famesoid x receptor mediated diseases, such as cholestasia, gallstone, non alcohol fatty liver disease, atherosclerosis, inflammation, cancer, etc..
Roivant Hepatology Ltd.

Thioaryl derivatives as gpr120 agonists

The present invention relates to thioaryl derivatives of formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of formula 1 according to the present invention promote glp-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc.

Composition for prevention, amelioration or treatment of metabolic syndrome

(b) is at least a kind of xanthine derivatives, the mass ratio of (a):(b) in the composition being 1:(0.001 to 5), are useful for the prevention, amelioration, or treatment of metabolic syndrome, disorders of lipid metabolism (for example, fatty liver, hyperlipidemia), obesity (for example, visceral fat accumulation, subcutaneous fat accumulation), or the like.. .

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University

Purified limonin glucoside for prevention and treatment of chronic diseases

One exemplary embodiment of the disclosure provides methods and compositions for treating a subject suffering from alcoholic liver disease, non-alcoholic fatty liver disease, type 2 diabetes, metabolic syndrome, cardiovascular disease, chronic kidney disease, and certain cancers, or a combination thereof, by administering a therapeutically effective amount of purified liminoid glucoside or a pharmaceutically acceptable salt thereof to the subject. In another exemplary embodiment, the disclosure provides methods and compositions for treating a subject suffering from elevated circulating concentrations of liver enzymes wherein the liver enzymes are selected from gamma glutamyl transferase, alanine amino transferase, alkaline phosphatase and complement fraction 3 or a combination thereof, the method comprising administering a therapeutically effective amount of purified liminoid glucoside or a pharmaceutically acceptable salt thereof to the subject wherein the treating results in a decreased circulating concentration of the liver enzymes..
The United States Of America, As Represented By The Secretary Of Agriculture

Compositions comprising 15-ohepa and methods of using the same

The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and their sequelae by administration of 15-ohepa.. .
Dignity Sciences Limited

Novel biomarkers for non-alcoholic fatty liver disease, and methods for detecting non-alcoholic fatty liver disease by using such biomarkers

The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis. Specifically, 35 kda protein fragment consisting of amino acid sequence expressed by sequence no.
Mcbi, Inc.

Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products.
Consejo Superior De Investigaciones Científicas

Compositions and methods for treating intestinal hyperpermeability

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

Methods and compositions for modulating gastrointestinal bacteria to promote health

Methods and compositions for treating medical conditions or improving health in which the composition is ingested in an amount sufficient to modify the proportion of bacteria in a gut microbiome of the individual ingesting the composition. The composition may comprise polydextrose or soluble com fiber, for example.
General Mills, Inc.

Method for assessment of hepatic function and portal blood flow

A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the stat test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate.
The Regents Of The University Of Colorado, A Body Corporate

Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity

The present invention relates to a composition comprising hyaluronic acid and dermatan sulphate for use in the treatment or prevention of overweight, obesity, insulin resistance, type 2 diabetes, fatty liver or dyslipidemia or for use in reducing food intake, inducing the feeling of satiety, reducing appetite, reducing body weight, preventing weight gain, reducing body fat, reducing fat formation, reducing blood cholesterol, maintaining normal blood cholesterol levels, reducing blood triglycerides, maintaining normal blood triglyceride levels or increasing insulin sensitivity. The composition can further contain collagen hydrolysate.
Bioiberica, S.a.

Composition for treating hyperlipidemia comprising oxyntomodulin derivative

The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate glp-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio.
Hanmi Pharm. Co., Ltd.

Thienopyridone derivatives useful as activators of ampk

Activators of ampk and therapeutic uses thereof the invention relates to compounds that are direct activators of ampk (amp-activated protein kinase) and their use in the treatment of disorders regulated by activation of ampk. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (nafld), non alcoholic steato-hepatitis (nash), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies..
Poxel

Compositions and methods for the treatment of inflammation

The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of inflammation may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Transmucosal delivery of engineered polypeptides

Formulations are provided that comprise compounds having inter alia good duration of action, high potency and/or convenient dosing regimens, and a permeation enhancer for transmucosal administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.

Compositions and methods for treating intestinal hyperpermeability

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

Compositions and methods for treating intestinal hyperpermeability

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

Modulation of nlgn4 expression, nk cell activity in non-alcoholic fatty liver disease (nafld)

The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting nlgn4 expression and thereby modulating the activity of nk cells. The present invention further relates to diagnosing a liver disorder by evaluating nlgn4 expression in nk cells..

Anti-fatty acid synthase polypeptide and use thereof

The present invention relates to a polypeptide that is capable of inhibiting transcription and expression of fatty acid synthase (fas) and the polynucleotides encoding therefor, as well as the use thereof. Specifically, the present invention relates to a polypeptide that can inhibit the transcription and expression of fas at the molecular level, the cellular level and in vivo, and can therefore prevent the overexpression of fas.
Tianjin Toptech Bio-science & Technology Co., Ltd.

Compositions and methods for the treatment of metabolic syndrome

The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis

5-cholesten, 3β, 25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virgini Commonwealth University

Methods for treating metabolic disorders using fgf

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies

Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease

The present invention relates to a pharmaceutical composition for the prevention and treatment of non-alcoholic fatty liver disease (nafld), including a conjugate prepared by covalently linking an insulinotropic peptide, a non-peptidyl polymer and an immunoglobulin fc region. The composition of the present invention maintains the in-vivo activity of the peptide at a relatively high level, and remarkably increases the blood half-life, thereby preventing triglyceride accumulation which is a typical feature of non-alcoholic fatty liver disease.
Hanmi Science Co., Ltd

Uses of hydroxyl polymethoxylflavones (hpmfs) and derivatives thereof

The invention discloses the uses of hydroxyl polymethoxylflavones and derivative thereof that are relative to inhibit adipogenesis and lower lipid accumulation, wherein the hydroxyl polymethoxylflavones is obtained from the peels of citrus genus plants. Therefore, the hydroxyl polymethoxylflavones that of a therapeutically effective amount not only can be a medical compound for treatment obesity or fatty liver, but also can be a food element..
Greenyn Biotechnology Co., Ltd

Methods of treating fatty liver disease

The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs.. .
Genzyme Corporation

Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of general formula (i) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease..
Genfit

Compositions and methods for treating non-alcoholic steatohepatitis

The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (epa-e). In some cases epa-e present may be at least 40% by weight in total of the fatty acids and their derivatives..
Mochida Pharmaceutical Co., Ltd

Hepatic neuromodulation to treat fatty liver conditions

According to some embodiments, a method of treating conditions affecting a liver of a subject is provided. The method may include delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus).
Metavention, Inc.

Compounds of estrogen-related receptor modulators and the uses thereof

The compounds according to formula (viii), their pharmaceutically acceptable acid or base addition salts, and the uses thereof. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for preparing medicaments for modulating estrogen related receptors (err), and treating metabolic diseases, such as high blood fat, fatty liver, hyperglycemia, diabetes, obesity.
Guangzhou Institute Of Biomedicine & Health, Chinese Academy Of Sciences

Method of treating non-alcoholic fatty liver disease and steatohepatitis

Or a metabolite thereof, or an ester of the compound of formula (i) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, x1 and x2 are as defined herein, is useful for treating non-alcoholic fatty liver disease (nafld) or non-alcoholic steatohepatitis (nash).. .

Use of humulus japonicus extract for preventing or treating metabolic disorders or fatty liver

A functional health food containing humulus japonicus extract as an active ingredient for preventing or improving metabolic disorders or for weight loss, a pharmaceutical composition containing humulus japonicus extract as an active ingredient for preventing or treating metabolic disorders, a functional health food containing humulus japonicus extract as an active ingredient for preventing or improving fatty liver, and a functional health food containing humulus japonicus extract as an active ingredient for inhibiting the accumulation of visceral fat.. .

Use of interleukin-22 in the treatment of fatty liver disease

The present invention relates to use of interleukin-22 (il-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of il-22 in decreasing the levels of transaminases is also provided..
Generon (shanghai) Corporation

Novel piperine derivatives and uses thereof

The present invention provides novel piperine derivatives. The present pharmaceutical or food composition containing a piperine derivative as an active ingredient is very effective in preventing or treating metabolic diseases including obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome.
Industry-academic Cooperation Foundation, Yonsei University

Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of overweight, obesity and associated pathologies

The present invention relates to the bifidobacterium cect 7765 strain, to its cell components, metabolites, and secreted molecules, to the combinations thereof with other microorganisms, and to compositions comprising the aforementioned products, as well as to the use of a strain of the bifidobacterium pseudocatenulatum species, or to using the cect 7765 strain for the prevention and/or treatment of obesity, overweight, hyperglycemia and diabetes, preferably type 2 diabetes mellitus, hepatic steatosis or fatty liver, dyslipidemia, metabolic syndrome, immune system dysfunction associated with obesity and overweight; and an unbalanced composition of the intestinal microbiota associated with obesity and overweight.. .

Methods of treating or preventing insulin resistance and associated diseases and conditions

Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (hsf1), or inducing the expression of heat shock protein 70 (hsp70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (i) or an epimer thereof, wherein ar, and r1-r6 are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality..

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.

Methods of treating fatty liver disease with helminth-derived glycan-containing compounds

The present invention provides a compound comprising a helminth-derived glycan and/or glycoconjugate thereof (e.g., a compound comprising a lewisx antigen (e.g., lnfpiii), a non-lewisx antigen (e.g., lnnt, ldn, and ldn derivatives), or a mixture of lewisx and non-lewisx antigens (e.g., sea)), useful as a therapeutic compound for treating or preventing diseases associated with fat accumulation in the liver. The compounds of the invention are useful for treating or preventing the development of a fatty liver disease in a subject that has the disease or is at risk of developing the disease, and inhibiting lipogenesis in hepatocytes.

Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as amino-transferases. The 1,3-diphenylprop-2-en-1-one derivatives of general formula (i) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease..

Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided.

Composition comprising chicory extract

The present invention relates to a chicory extract for allowing reduction or control of body weight or limitation of body weight gain, reduction or limitation of increase of fat storage, of fatty liver, of liver triglycerides level, of hypertriglyceridemia, of glycemia level, of insulinemia level, of insulin resistance, and/or of different factors of metabolic syndrome, and to a composition comprising such an extract.. .

Mitochondrial-derived peptide mots3 regulates metabolism and cell survival

Mots3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using mots3 and pharmaceutical compositions thereof are disclosed herein..

Composition containing triticum aestivum lamarck leaf extract or fraction thereof as active ingredient

The present invention relates to a pharmaceutical composition for prevention and treatment of hyperlipidemia or fatty liver disease, the composition containing dichloromethane fractions as an active ingredient amongst fractions obtained by fractionating the alcohol extract of triticum aestivum lamarck leaves in an order of dichloromethane, ethyl acetate, and butanol.. .

Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and t2d

The invention provides pharmaceutical compositions, methods for the treatment of and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g.

Method for lowering blood glucose and treating hepatic disease, obesity and diabetes

The present invention provides methods of administering a dendrobium polyphenol in an amount effective to lower blood sugar, treat hepatic disease, obesity or diabetes. Exemplary hepatic disease includes fibrosis, fatty liver and hepatitis.

Pharmaceutical composition for preventing or treating diabetes or fatty liver containing a cyp4a inhibitor as an active ingredient

The present invention relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver, and more specifically relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver containing a cyp4a (cytochrome p450a) inhibitor as an active ingredient. According to the present invention, the cyp4a inhibitor suppresses endoplasmic reticulum stress, reduces the blood insulin concentration and suppresses apoptosis of liver cells, and hence exhibits effects in preventing or treating diabetes or fatty liver..

Method for the treatment of fatty liver disease

The invention provides a method of treating, inhibiting and/or preventing fatty liver disease in a patient in need thereof, comprising administering an effective amount of a cyclohexenone compound of the following formula (i) to said patient,. .

Compounds for control of appetite

This invention relates generally to neuropeptide y (“npy”) y4 receptor agonists including pancreatic polypeptide (pp), analogs thereof, and peptide fragments of pp, e.g. Pp(32-36), and analogs thereof, to pharmaceutical compositions containing such y4 receptor agonists, and to methods for treatment of mammals using the same.



Fatty Liver topics:
  • Fatty Liver
  • Liver Disease
  • Alcoholic Fatty Liver
  • Steatohepatitis
  • Nonalcoholic Steatohepatitis
  • Metabolic Syndrome
  • C Syndrome
  • Hyperlipidemia
  • Insulin Resistance
  • Hepatitis A
  • Dyslipidemia
  • Atherosclerosis
  • Arteriosclerosis
  • Cardiovascular
  • Vascular Diseases


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Fatty Liver for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Fatty Liver with additional patents listed. Browse our RSS directory or Search for other possible listings.


    2.0114

    file did exist - file did put13356

    4 - 1 - 253